Freda Lewis-Hall - 24 Mar 2026 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Reporting relationship: Director
Issuer ticker: PYXS
Reported as of: 24 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Mar 2026, 17:08:25 UTC
Prior SEC filing: 26 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Jitendra Wadhane, Attorney-in-Fact for Freda Lewis-Hall

Key filing fact

Freda Lewis-Hall filed Form 4 for Pyxis Oncology, Inc. (PYXS) on 25 Mar 2026.

Key facts

This page summarizes Freda Lewis-Hall's Form 4 filing for Pyxis Oncology, Inc. (PYXS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 25 Mar 2026, 17:08.

Change

Previous filing in this sequence was filed on 26 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001437909 Primary reporting owner

Lewis-Hall Freda C

Relationship: Director
Address: C/O PYXIS ONCOLOGY, INC., 321 HARRISON AVENUE, 11TH FL. SUITE 1, BOSTON
Signature: /s/ Jitendra Wadhane, Attorney-in-Fact for Freda Lewis-Hall
Signature date: 25 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PYXS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +45,867
Change %
Price: $0.000000^*
Shares after: 45,867
Date: 24 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 45,867
Exercise price: $1.36
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.